The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 8 of the 112 sources its claims cite were checked for support.
Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review
Open accessAbstract
Introduction: The availability and affordability of safe, effective, accessible, and high-quality essential medicines is a critical benchmark for achieving the right to good health, and it is also one of the goals of the global health development agenda. To that end, it is critical to conduct rigorous studies to identify the major challenges confronting developing countries, particularly those in Africa. Objective: The purpose of this review was to identify the major challenges that Africans face in obtaining reasonably priced and readily available essential medicines. Methods: Generally the Boolean operators "AND" and "OR" were employed. Making progress also involves using duplicate checks, field definitions, and comparisons of articles and criteria. The analysis included all English-language papers published in any African country between 2005 and 2022, depending on the year of publication. The technique searches electronic databases for key phrases related to essential medication availability and affordability, such as PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar. Results: A total of 91 articles; by using search engines and handpicking including duplicates, were primarily searched. The electronic database search earned 78 articles while only eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries. Inadequate human resources, financial constraints, high cost of available medications on the market, poor inventory management, manual consumption forecasting, inefficiencies in drug registration, and trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations. Conclusion: This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges. The primary challenge, according to the review research, is a lack of adequate financing to pay for an appropriate set of essential medications, which account for a significant portion of household spending.
Overview
CoChat Summary
TL;DR
This scoping review synthesizes 11 studies on barriers to essential medicine availability and affordability in African countries, identifying financing, pricing, supply-chain, human-resource, regulatory, and governance challenges. It concludes that availability remains below the WHO 80% benchmark and that medicines are often unaffordable, especially for poor households.
Key findings
- The review included 11 studies: 5 qualitative, 4 cross-sectional, and 2 mixed; 5 (50%) were from East African countries. Reported barriers included inadequate human resources, financial constraints, high market prices, poor inventory management, manual consumption forecasting, inefficient drug registration, and TRIPS-related regulations.
- Availability was low: in one 8-country survey of 3,353 hospitals and primary care facilities, mean availability of 12 essential medicines ranged from 22% to 40%; in Uganda, average availability of tracer drugs in public pharmacies was 63.3%; in South Africa, public-sector median availability of lowest-price brands and generics was 10% and 75%, while private-sector median availability was 28.6%.
- Affordability was poor: high-cost essential medicines required the lowest-paid government employee to work 15 days for a one-month supply; branded medicines were 13.8 times more expensive than generics, and generics and brands were purchased at 2.9 and 32.6 times international reference prices, respectively. In Ethiopia, 45.6% of non-buyers cited unavailability, 45.7% cited expense, 8.7% cited ineffectiveness, and 11.8% forwent treatment due to cost.
- The review reports that African-region median availability of essential medicines was 61.5% versus 27.3% for nonessential medicines; public-sector median availability was 40% and private-sector 78.1%, compared with 6.6% and 57.1% for nonessential medicines. The conclusion states availability does not exceed 65% and purchasing costs are unaffordable.
Methods
- Scoping review searching PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar, using Boolean operators “AND” and “OR,” field specifications, duplicate checks, and article/criteria comparisons.
- Inclusion covered English-language, open-access PDF articles on challenges to essential medicine availability, affordability, and accessibility in African countries; the abstract and inclusion criteria state 2005–2022, while the search strategy states 2005–2023. Dissertations, abstracts, editorials, clinical views, non-African studies, and abstract-only publications were excluded.
- Methodological quality was assessed with PRISMA and an EBL critical appraisal tool; three reviewers independently assessed full texts, with 85.7% inter-observer agreement. Validity thresholds were <75% low quality, 75–90% moderate, and >90% high; most included studies were medium reliability, with 2 (20%) rated excellent.
Limitations
- Stated by the paper: the review does not examine one influencing factor in detail or all influencing factors, but analyzes factors frequently mentioned in the reviewed articles; it also does not assess challenges across the continent as a whole and ignores national economies, policies, and regulations affecting availability and affordability.
- Evident from the text: the search and inclusion numbers are inconsistent—the abstract reports 91 articles primarily searched and 78 from electronic databases, while the Results section reports 88 studies initially retrieved and 11 reviewed—and the date range is reported as both 2005–2022 and 2005–2023.
- Evident from the text: only 11 studies were included, most were hospital-based, 5 (50%) were from East African countries, and most were rated medium reliability, limiting continent-wide generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 4 Not valid · 80 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Transportation is widely acknowledged as a challenge in obtaining pharmaceutical care due to road closures, poor road construction, and transportation shortages; however, it is underexplored in terms of the clarity needed for tackling more immediate health and transportation policy interventions.27,28”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Transportation
What the sources say
- Partly supportedcites [27] Chandani, 2012, Am J Trop Med Hyg sourceExperimental — accuracy not yet measured
The Results section, “Precondition 4: Availability of appropriate transportation” (page unavailable), reports that community health workers identified unavailable or unreliable transport, distance, and rainy-season travel as obstacles to obtaining medicines. It notes dirt roads but does not identify road closures or poor road construction as causes. The evidence also concerns workers collecting medicine supplies, rather than patients obtaining pharmaceutical care generally. (LLM, conf=0.86)
- Not checked yetcites [28] Kanda, 2015, Int J Acad Res Account Financ Mang Sci source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Drug Registration and Regulation
What the sources say
- Not checked yetcites [36] Kefale B. Explore the challenge in medicines registration process in Ethiopia: qualitative phenomenological study; 2020.
- Partly supportedcites [38] Moran, 2011, PLoS Med sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) supports the general framing: a 2010 WHO study found 90% of sub-Saharan African MRAs 'in a situation which did not allow them to adequately carry out regulatory functions,' and 'growth in African regulatory capacity is not keeping up with these new challenges' posed by the growing demand to assess novel ND products. The Discussion likewise calls the current system inefficient and resource-wasteful, and the proposals list joint good manufacturing practices plant inspections and joint dossier review. But no passage in our copy — searched for 'quality testing procedures', 'quality control laboratories', 'batch release/testing' — identifies quality testing procedures as a registration challenge that failed to keep pace with demand; that specific element of the citing sentence is not attributable to this paper. (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low investment in essential medicines for health, a lack of comprehensive health financing policies and strategic plans, extensive out-of-pocket payments, a lack of social safety nets to protect the poor, poor financial management, inefficient resource allocation and use, and weak mechanisms for coordinating partner support constrain health financing in the African region.30,41”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > DovePress 453
What the sources say
- Could not verifycites [30] Droti, 2019, BMJ Glob Heal sourceExperimental — accuracy not yet measured
The Discussion says the surveyed countries had very limited public-sector budgets for medicine procurement, but it does not identify poor financial management as a constraint on health financing. Searches for financial management and resource allocation found no passage addressing that point. (LLM, conf=0.72)
- Supportedcites [41] Kirigia, 2008, BioMed Cent source
The Challenges section explicitly lists weak financial management among the characteristics of health financing in the African Region. That supports the attributed claim that poor financial management constrains health financing there. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
56 more claims
Create a free account to see all 123 claims and to verify the 104 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 38
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
“The electronic database search earned 78 articles”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Results
“the preliminary information retrieval system across all databases resulted in 88 studies (68 from Pub Med).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
Reported 50 · recomputed 45.454545
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“the majority of studies were of medium reliability, with 2 (20%) being of excellent quality.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > The Listed Studies' Methodological Quality
Reported 20 · recomputed 18.181818
Citations
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928 · cited 2×
“Medicines consume up to 20–60% of health expenditure in developed and transitional countries, and in developing African nations, nearly 90% of the population buys medicines out of pocket, making medicines the second-largest item of family spending after food.(32) Over 50 price and affordability surveys were conducted…”
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661 · cited 3×
“To be available and affordable drugs should be used in a suitable, safe, cost-effective, secure, and accessible way.(7) Given that from 2001 to 2007, just 30% of all both private and public health facilities in African countries had access to vital medicines, more than 70% of the population in Africa was impacted.”
InfluentialMendis, S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.033647 · Cited by 487 · cited 3×
“The World Health Organization and Health Action International recommend using the LPGW’s income as a benchmark for comparing the cost of medication care to the availability of medications.(2,20) Since the current global minimum salary is US $ per day, the lowest-paid unskilled government employee’s daily wage will be…”
InfluentialA critical appraisal tool for library and information research
Glynn, L. (2006) · Library Hi Tech · doi:10.1108/07378830610692154 · Cited by 345 · cited 2×
“The calculation for overall validity was: (Y+N +U=T); If Y/T ≥75% or if N+U/T ≤ 25% then it can safely conclude that the study is valid.(23) A score of less than 75% was considered low quality, 75% to 90% was considered moderate quality, and more than 90% was considered high quality.”
Modisakeng, C., Matlala, M., Godman, B., & Meyer, J. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05080-1 · Cited by 130 · cited 2×
“According to the World Bank, approximately 80% of the African continent’s population, primarily those in the middle and lower income brackets, rely on public health facilities to access health care.(25) Several factors have been linked to affecting the accessibility of essential medicines in Africa’s public and privat…”
Revisiting the issue of access to medicines in Africa: Challenges and recommendations
Adebisi, Y. A., Nwogu, I. B., Alaran, A. J., Badmos, A. O., Bamgboye, A. O., Rufai, B. O., Okonji, O. C., Malik, M. O., Teibo, J. O., Abdalla, S. F., et al. (2022) · Public Health Challenges · doi:10.1002/puh2.9 · Cited by 111 · cited 6×
“Many people living in Africa have a problem with accessing medicines and this undoubtedly contributes to the poor health metrics of most countries in the region.(4) The availability and cost of medications are considered two of the most crucial factors for providing healthcare users with quality healthcare, along with…”
InfluentialHealth challenges in Africa and the way forward
Kirigia, J., & Barry, S. (2008) · International Archives of Medicine · doi:10.1186/1755-7682-1-27 · Cited by 110 · cited 4×
“Extreme shortages of highly qualified health professionals, rooted in African countries, have been exacerbated by disparities in labor distribution and brain drain in this crisis, jeopardizing the delivery of effective public health interventions to those in need, particularly in remote rural areas.(16,41) Professiona…”
InfluentialMajor Public Health Problems in Nigeria: A review
Muhammad, F., Abdulkareem, J. H., & Chowdhury, A. A. (2017) · South East Asia Journal of Public Health · doi:10.3329/seajph.v7i1.34672 · Cited by 79 · cited 1×
“43”
Chandani, Y., Noel, M., Pomeroy, A., Andersson, S., Pahl, M. K., & Williams, T. (2012) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2012.11-0781 · Cited by 74 · cited 1×
“27,28 Outlined that transportation infrastructure affects the total supply chain performance of pharmaceuticals due to poor infrastructure construction, development, heavy traffic over-crowding in large cities, and poor availability in rural areas of Africa.”
Research works printed but not linked: 16
- World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies WHO Guideline on Country Pharmaceutical Pricing Policies. World Health Organization; 2020:1–70.
- Bruno, 2015, J Pharm Care Heal Syst, 1, 10.4172/jpchs.s2-006 · doi:10.4172/jpchs.s2-006
- Latifah, 2019, Rev Artic, 10, 67
- Fredrick, 2016, IOSR J Business Manag, 18, 63, 10.9790/487x-1810066375 · doi:10.9790/487x-1810066375
- Obuaku, 2014, Afr Soc Rev, 18, 42
- Zuma, 2019, World J Pharm Res, 8, 1532, 10.20959/wjpr20199-15303 · doi:10.20959/wjpr20199-15303
- Abiye, 2013, J Appl Pharma Sci, 3, 101, 10.7324/japs.2013.31017 · doi:10.7324/japs.2013.31017
- Irene, 2016, J Health Med Nurs, 27, 45
- Mendis, 2007, Lancet, 85, 279, 10.2471/blt · doi:10.2471/blt
- World Health Organization. Measuring affordability and price availability, components. In: Medicine Prices, Measuring Affordability and Price Availability, Components. World Health Organization; 2008:1–310.
- Machemedze MMR, Munyuki E. Literature review on bottlenecks to essential medicines production and procurement in East and Southern Africa; 2013:1–23.
- Modisakeng, 2020, MBC Heal Serv Res, 1, 1
- Osei-Assibey, 2017, J Biomed Pharm Res, 6, 100
- 2019, Ensuring Access to Medicines in East Africa: Lessons from India
- Baker, 2009, Am Med Assoc J Ethics, 2009, 527
- Mohammadshahi, 2019, Shiraz E Medical J, 20, 1, 10.5812/semj.87079.review · doi:10.5812/semj.87079.review
Cited by
Okesanya, O. J., Amisu, B. O., Adigun, O. A., Ahmed, M. M., Agboola, A. O., Kab, T., Eshun, G., Ukoaka, B. M., Oso, T. A., Ogaya, J. B., et al. (2025) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-024-00236-x · Cited by 34
“Over time, this results in a vicious cycle where the financial pressure on the healthcare system undermines the overall economic development of the region [86, 87].”
Gaetano, S. D., Ponzo, E., Midiri, A., Mancuso, G., Filippone, D., Infortuna, G., Zummo, S., & Biondo, C. (2025) · Hygiene · doi:10.3390/hygiene5020018 · Cited by 42
Disparities in availability of new cancer drugs worldwide: 1990-2022
Li, M., Ka, D., & Chen, Q. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-015700 · Cited by 28
“34 35 For example, countries may not have sufficient funds to cover new cancer drugs in their national formulary or to support infrastructure for administrating specialty cancer therapies.”
Personalized medicine and health equity: overcoming cost barriers and ethical challenges
Francisco, K. K. Y., Apuhin, A. E. C., Maravilla, N. M. A. T., Byers, M. C., Karim, H. B. A., Tan, M. J. T., & AlDahoul, N. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-025-02710-0 · Cited by 30
“Challenges such as unestablished drug regulatory programs, logistics, weak health systems, and resource scarcity make acquiring these medications nearly impossible [40, 41].”
The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa
Madu, C. V., Alum, E. U., Aloh, H. E., Ugwu, O. P.-C., Obeagu, E. I., Uti, D. E., Egba, S. I., Ukaidi, C. U. A., & Alum, N. B. (2025) · Medicine · doi:10.1097/md.0000000000042300 · Cited by 34
Symochko, L., Pereira, P. A. D. S., Demyanyuk, O., Pinheiro, M. N. C., & Barceló, . (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32716 · Cited by 24
“…and infection control in medical institutions and agricultural enterprises; 5) limited access to high-quality and affordable medicines, vaccines and diagnostic tools [46,47]; 6) low level of population awareness and 7) knowledge and lack of control over compliance with legislation [48,49].”
BackgroundMalematja, D. N., Nkosi, E. M., & Nene, S. E. (2025) · Curationis · doi:10.4102/curationis.v48i1.2696 · Cited by 19
Kumar, P., Anshu, Lionis, C. D., Andoko, D., Rahman, Z., Anastasaki, M., & Ateghang-Awankem, B. (2025) · Journal of Surgical Specialties and Rural Practice · doi:10.4103/jssrp.jssrp_8_25 · Cited by 29
Digital Transformation in Pharmaceutical Supply Chain: An African Case
Ashiwaju, B. I., Agho, M. O., Okogwu, C., Orikpete, O. F., & Daraojimba, C. (2023) · Matrix Science Pharma · doi:10.4103/mtsp.mtsp_16_23 · Cited by 27
Angula, T. N., & Dongo, A. (2024) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2024.26.2.0071 · Cited by 20
“A scoping review of African countries by Yenet et al. [1] found that the median availability of essential medicines in the public sector was 40%, compared with 78.1% in the private sector.”
BackgroundInfluentialChabalenge, B., Sahota, T. S., Ermolina, I., & Tanna, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708784 · Cited by 19
Ιωάννου, Π., & Baliou, S. (2024) · Antibiotics · doi:10.3390/antibiotics13070593 · Cited by 17
“In many low-and middle-income countries, growing health expenditure is associated with a growing inaccessibility to treatment [25].”
BackgroundWilliams, G. F., Alberto, L., Taha, M., & Papathanassoglou, E. D. E. (2025) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2025.104032 · Cited by 17
Hire, A. J., & Franklin, B. D. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-04858-w · Cited by 16
“For example, over half of Africa’s population lacks access to even essential medications, with poverty playing a major role [53].”
BackgroundHot Melt Extruded High-Dose Amorphous Solid Dispersions Containing Lumefantrine and Soluplus
Li, S., Zhang, Z., Gu, W., Gallas, M., Jones, D., Boulet, P., Johnson, L. M., de Margerie, V., & Andrews, G. P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124676 · Cited by 16
Ogunyemi, A. O., Balogun, M., Ojo, A. E., Welch, S., Akeju, D., Onasanya, O. O., Omotayo, A., Shu-Ting, L., & Hirschhorn, L. R. (2025) · BMC Public Health · doi:10.1186/s12889-025-23965-w · Cited by 18
“When essential drugs are unavailable or too costly and beyond their reach, their health conditions can deteriorate, leading to more serious complications that may require hospitalizations [59].”
Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder
Yocum, A. K., & Singh, B. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01606-8 · Cited by 16
“However, developing countries face significant challenges in medication accessibility due to limited healthcare infrastructure, economic constraints, and higher costs of newer medications [69].”
Strengthening healthcare systems to prevent antimicrobial resistance in LMICs: it is time to act
Sorn, V. (2026) · Journal of Global Health · doi:10.7189/jogh.16.03007 · Cited by 13
Availability, pricing, and affordability of essential medicines for pediatric population in Malawi
Chiumia, F. K., Chithope-Mwale, C., Abikoloni, F., Matchaya, V., Gaviyawo, T., & Khuluza, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379250 · Cited by 14
Save life! Optimization of dynamics for pharmaceutical distribution performance
Mwakyeja, B., & Kimario, H. F. (2024) · Management Matters · doi:10.1108/manm-03-2024-0018 · Cited by 14
Chance, E. A., Théophile, P., & Loe, L. R. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05133-0 · Cited by 14
“The cost-effectiveness and community-based nature of traditional medicine [55] make it particularly important for underserved communities [56].”
Organ transplantation in Africa: Confronting socioeconomic, cultural, and infrastructural hurdles
Olawade, D. B., Odetayo, A., Marinze, S., Egbon, E., & Chinwah, V. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103516 · Cited by 18
Elliss, H., Proctor, K., Robertson, M., Bagnall, J. P., & Kasprzyk‐Hordern, B. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06097-3 · Cited by 12
“It is important to note that only in certain countries, prescription data will be able to predict usage and assist with these challenges [20, 21].”
Owusu, R., Bawua, S. A., Kwarteng, E. B., Baatiema, L., & Nonvignon, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311994 · Cited by 9
Use of Essential Medicines for Pain Relief and Palliative Care: A Global Consensus Process
Pastrana, T., Lima, L. D., Dudgeon, D. J., Voeuk, A., Ahmed, E., & Radbruch, L. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.10.024 · Cited by 9
Increasing Access to Palliative Care in Cameroon: Progress, Gaps, and Recommendations
Bassah, N., Salas, A. S., Ambe, N. C., & Ngah, N. E. (2024) · Nursing Reports · doi:10.3390/nursrep14040263 · Cited by 8
Zondi, M., & Mkhize, S. W. (2025) · Healthcare · doi:10.3390/healthcare13182343 · Cited by 12
“Facilities in the district frequently experience inadequate supplies of essential medication and equipment [17], alongside vacancy rates for professional nurses that remain disproportionately high in rural Eastern Cape health services [18].”
Research of affordability to essential medicines for coronary heart disease in Ukraine
Білоусова, Н. А., Ткаченко, Н. О., Kozhuharyova, N., & Долженко, М. М. (2025) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2025.2470841 · Cited by 9
“This approach may be limited by the lack of medicines in pharmacy and health centers, the lack of ability to buy or pay for medicines from one’s own budget (Yenet et al., 2023, pp. 443–458).”
Slamang, W., Scott, C., & Foster, H. (2024) · Pediatric Rheumatology · doi:10.1186/s12969-024-00997-x · Cited by 7
“Additionally, pharmaceutical services in institutions across Africa have required support from several globally funded programs to address operational gaps [43–46].”
BackgroundParmaksiz, K., Asingizwe, D., Gichohi, A. K., & Karengera, S. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2390653 · Cited by 7
Mayunga, C., Msaki, E. B., Katabalo, D. M., & Mwita, S. M. (2025) · The Journal of Medicine Access · doi:10.1177/27550834251371865 · Cited by 8
Yang, S., Bai, C., Zhao, Y., Wang, J., Jin, H., Harris‐Roxas, B., Liu, Y., Shen, F., Zhao, H., Ma, L., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1732011 · Cited by 9
“However, to achieve long-term improvements, systemic policies are needed to strengthen resource allocation and ensure adequate healthcare facilities, medicines, and personnel in underserved regions (80, 81).”
Belinga, L. N., Espourteille, J., Njamnshi, W. Y., Zeukang, A. Z., Rouaud, O., NJAMNSHI, A. K., Allali, G., & Richetin, K. (2024) · Neurodegenerative Diseases · doi:10.1159/000538623 · Cited by 7
“The high costs associated with neuroimaging tools add to the cost of specialized physician consultation, which leads some patients to seek alternative solutions, including traditional medicine or religious practices [2, 29, 30].”
BackgroundVilla, S., de Colombani, P., Dall’Olio, L., Gargioni, G., & Raviglione, M. C. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-014630 · Cited by 6
Hwang, J., Dey, I. D., Ayanlowo, O. O., Flower, C., King, A., Johnson, N. A., Ima-Edomwonyi, U., Olasebikan, H., Falasinnu, T., Pandian, V. D., et al. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1414490 · Cited by 6
“Insuf fi cient diagnostic centers and limited access to diagnostic tools, compounded by understocked pharmacies and inadequate intensive and emergency care facilities, further impede access to care in the region (Mody, 2017; Atobatele et al., 2022; Nicholas et al., 2022; Yenet et al., 2023).”
BackgroundPandey, A., & Mishra, A. (2025) · Journal of Human Rights and Social Work · doi:10.1007/s41134-024-00361-9 · Cited by 7
“Over half of the Africa’s population lacks such access (Yenet et al., 2023).”
Mudenda, S., Simbaya, R., Moonga, G., Mwaba, F., Zulu, M., Tembo, R., Chiyangi, H. K., Vlahakis, P. A., Mohamed, S., Lubanga, A. F., et al. (2025) · Pharmacology & Pharmacy · doi:10.4236/pp.2025.161001 · Cited by 6
Mekasha, Y. T., Getahun, H., Tegegne, A. A., & Hasen, G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1452875 · Cited by 8
Improving access to essential medicines via decision-aware machine learning
Chung, A. T.-H., Abdulai, J., Bayoh, P., Sandi, L., Smart, F., Bastani, H., & Bastani, O. (2026) · Nature · doi:10.1038/s41586-026-10433-7 · Cited by 9
Alemu, A., Meseret, F., Keneni, M., Wondimneh, F., Legesse, H., Mossie, Y., Teshager, T., Tamiru, E., Tizau, D., & Asfaw, T. N. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1546455 · Cited by 6
“Moreover, the high proportion of TM use might be linked to the unavailability of scienti fi cally proven modern treatments for certain conditions, including both non-communicable and communicable diseases (59 – 61).”
Alemayehu, T. T., Woldeyohanins, A. E., Gebremeskel, E. D., Geremew, G. W., Wassie, Y. A., Mekete, M. D., Minwagaw, T., Abebe, T. B., & Seifu, K. (2025) · Conflict and Health · doi:10.1186/s13031-025-00697-7 · Cited by 6
“Poor inventory management can result in overstocking, which leads to wastage due to drug expiration, or under - stocking, which leaves critical medicines unavailable when they are needed most [10, 11].”
Hassen, H. K., Mekasha, Y. T., Tegegne, A. A., & Özalp, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1484649 · Cited by 5
Saeed, A. A., Zamel, A. M. A., Ahmed, A. A.-W. G., Abdelrahman, D. A. A., Abdoon, E. F. A., Mousa, N. H. M., Salim, R. I. A., Mahgoub, S. M. A., Mohammed, S., & Badi, S. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004867 · Cited by 5
“The collapse of employment rising inflation and loss of income leave many unable to purchase essential medicines even when available [17,18].”
Dehury, R. K., Ahmad, I., Behera, M. R., Manchana, V., Dehury, P., Behera, D., & Desouza, N. V. E. (2024) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2024.100455 · Cited by 5
Ogbodu, O. M., Mrara, B., & Sewani-Rusike, C. R. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101349 · Cited by 7
Impact of Drug Price Regulation on Patient Access to Medicines: A Systematic Review
Ashiwaju, B. I., Orikpete, O. F., Alade, E. Y., Raji, A., Adesanya, A. O., & Nwankwo, T. C. (2023) · Matrix Science Pharma · doi:10.4103/mtsp.mtsp_23_23 · Cited by 6
Inequity in access to medications among communities in Eastern Ethiopia: a decomposition analysis
Edessa, D., Kumsa, F. A., Dinsa, G. D., & Oljira, L. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12963-8 · Cited by 7
“However, approximately 2 billion people lack access to essential medicines globally [9], with low-income nations experiencing greater unmet needs [10, 11].”
Afifi, M., Hemachandra, N. N., Sikandar, Q., Hajjeh, R. A., Loi, U. R., Läser, L., Qato, D. M., Abdul, Z. S., Chikvaidze, P., Abbas, R. A., et al. (2024) · Reproductive Health · doi:10.1186/s12978-024-01805-1 · Cited by 4
“However, access to quality-assured and affordable medicines is challenging in many countries [22].”
BackgroundShah, H., & Dioso, R. I. (2025) · medtigo Journal of Medicine · doi:10.63096/medtigo30623218 · Cited by 5
Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals
Lee, C., Gross, C. P., & Miller, J. E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.6060 · Cited by 5
Obeagu, E. I., Abdulrahman, A. O., & Anetor, J. I. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004641 · Cited by 4
“Review external shocks like pandemics or natural disasters can further disrupt supply chains and delay drug deliveries [ 7 ] .”
The Critical Role of Medicine Adherence in Management of Chronic Conditions: A Review Article
Katende-Kyenda, L. N. (2026) · Journal of Mind and Medical Sciences · doi:10.3390/jmms13010002 · Cited by 4
“Moreover, Yenet et al. (2023) [25] concluded that structural barriers, such as insufficient access to drugs in certain areas and high out-of-pocket expenditures further exacerbate non-adherence.”
Addressing challenges along the ‘access cascade’ for new TB regimens
Servello, J., de Colombani, P., Dall’Olio, L., Gargioni, G., & Raviglione, M. C. (2026) · IJTLD OPEN · doi:10.5588/ijtldopen.25.0610 · Cited by 4
Nsengimana, A., Biracyaza, E., Manirakiza, A., Nsekonziza, Y., Niyonsenga, E., Ntirenganya, F., & Umumararungu, T. (2024) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s489143 · Cited by 4
Key stakeholders’ views on the causes of medicine stock-outs in Mauritania: A qualitative study
Ahmed, M. A. A., Coulibaly, I. M., Ravinetto, R., Buitrago, V. T., & Dujardin, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0304930 · Cited by 4
“They undoubtedly contribute to poor health indicators in many African countries, making them a significant obstacle to achieving Universal Health Coverage [6–11].”
Supapaan, T. S., Somsorn, S., Saensupha, N., Songmuang, T., Songmuang, A., Jaturapattarawong, A., Sripa, S., Jinatongthai, P., & Napaporn, J. (2024) · Pharmacy Practice · doi:10.18549/pharmpract.2024.4.3057 · Cited by 3
“27,28 Moreover, patients occasionally acquire unfamiliar brands through mail deliveries.”
Kalison, N., Luoga, P., Nyangi, E., & Frumence, G. (2025) · Discover Health Systems · doi:10.1007/s44250-025-00252-4 · Cited by 3
“In South Asia and Sub-Saharan Africa, nearly 50% face this issue, mainly due to poor procurement management and limited funding [12].”
Debessa, K. C., Negeri, K. G., & Dangisso, M. H. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004310 · Cited by 4
“Another important barrier is the existence of chronic medication, laboratory services stockouts, and reimbursement delays for providers within the Ethiopian CBHI, which also resonates with the challenges faced in community-based health programs in many African nations [43,44].”
Access to essential medicines during the Sudanese civil war: a cross-sectional study
Ahmed, A. B. M., Hemmeda, L., Alrawa, S. S. K., Abukhris, D. K. H., Suliman, D. K. E. E., Hamad, E., Mohammed, F., Fadlalmoula, G. A. A. G. A., Rhamttallah, M., Alsedig, M. F. A., et al. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-025-02647-4 · Cited by 3
Uahupirapi, K., Shifotoka, S., & Nangombe, V. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00799-1 · Cited by 5
“Studies across sub-Saharan Africa have documented comparable issues with public sector medicine availability, highlighting the regional nature of these challenges [8–10 ,”
InfluentialDashti, R., Jahandoost, A., Fardadidokht, S., Hosseini, S. A., Mojarad, O., Golsefid, A. T., Gross, J. D., & Samadi, A. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00562-4 · Cited by 4
“• Limited access to high-quality and affordable medications remains a significant issue in many low-and middle-income regions, undermining consistent and equitable care [37].”
Ibrahim, S., Muntaka, A. S., Manso, J. F., Tamakloe, E. A., Mohammed, A. L., & Kuusua, S. T. (2025) · The International Journal of Logistics Management · doi:10.1108/ijlm-11-2024-0714 · Cited by 4
Nyarko, S., Atinga, R. A., & Mahama, J. C. (2026) · Health Policy and Planning · doi:10.1093/heapol/czag035 · Cited by 3
“Even where opioids are listed as essential medicines, financial barriers and limited insurance coverage further restrict access (Vranken et al. 2020, Mathewos Oridanigo et al. 2021, Yenet et al. 2023, Rosa et al. 2025).”
Mazhindu, T., Nagy, M., Twesigomwe, D., Agesa, G., Scholefield, J., & Masimirembwa, C. M. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70268 · Cited by 3
Hoffman, R. M., Phiri, K., Kalande, P., Whitehead, H. S., Moses, A., Rockers, P. C., Tseng, C., Talama, G. C., Banda, J. C., van Oosterhout, J. J., et al. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04492-y · Cited by 3
Time and cost involved in measuring access to medicines: the case of Albania
Petro, E., Joosse, I. R., Siebers, A. C. M., Martopullo, T., Hart, R. P. M., Mantel-Teeuwisse, A. K., van den Ham, H. A., & Suleman, F. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07168-5 · Cited by 3
Higgins, C. R., Wilfinger, M. J., Doohan, J., Okorigwe, E. M., Ashenef, A., Fentie, A. M., Chikowe, I., Kumwenda, H. S., Ndom, P., Saidu, Y., et al. (2026) · JCO Global Oncology · doi:10.1200/go-25-00118 · Cited by 6
Okpalanwaka, I. F., Anazodo, F. I., Chike-Aliozor, Z. L., Ekweozor, C. A., Ochie, K. M., Oboh, O. F., Okonkwo, F. C., & Njoku, M. F. (2024) · Cureus · doi:10.7759/cureus.69136 · Cited by 3
“Yet over 80% of the population of most SSA countries get access to medicine by paying out-of-pocket [119].”
Anagaw, Y. K., Feleke, M. G., Mekuriaw, E. T., Mitku, M. L., Limenh, L. W., Bayleyegn, Z. W., Worku, M. C., Denekew, T., Geremew, D. T., & Ayenew, W. A. (2024) · SAGE Open Medicine · doi:10.1177/20503121241272738 · Cited by 2
“18 Despite such heavy spending, one-third of the world’s population lacks access to essential medicine—up to one-half in Asia and Africa.”
BackgroundZhou, T., & Getele, G. K. (2025) · Journal of Health Organization and Management · doi:10.1108/jhom-04-2024-0136 · Cited by 2
Birmeh, C., Urio, O., & Wilmshurst, J. M. (2025) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2025.101200 · Cited by 3
Siefen, T., Flamme, H., Gwaza, L., & Lehnert, R. (2025) · Journal of Public Health · doi:10.1007/s10389-025-02499-w · Cited by 2
Adedeji, A. A., Abdus-Salam, I. A., Adedeji, A. A., Omotayo, L., Oreagba, I. A., Adedeji, K. A., Ayodele, B. J., Adam, E. M. E., Olaleye, O. N., Tambo, E., et al. (2025) · Discover Medicine · doi:10.1007/s44337-025-00395-6 · Cited by 2
“A scoping review by Yenet et al. [12] highlights the ongoing challenges in ensuring the availability and affordability of essential medicines in African countries showcasing need-gap that PHP's could address of health disparities at system level through targeted interventions.”
Awojide, S. H., Ajayi, O. P., Adeyemo, A. G., Olabintan, O. M., Obunadike, C. V., Adetunji, J. B., & Anifowose, A. J. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00301-0 · Cited by 3
Munzhedzi, M., Chigome, A., Miljković, N., Moore, C. E., Campbell, S., Godman, B., & Meyer, J. C. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_175_25 · Cited by 3
Mutsvangwa, S., Tongofa, M., & Chingwaru, T. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2620332 · Cited by 2
Effectiveness of a village emergency care model: a pilot intervention in rural Tanzania
Sirili, N. S., Hyuha, G., Kiwango, G., Nyamle, N., Kilonzi, M., Mussa, R. Y., Frumence, G., Sawe, H. R., & Mfinanga, J. A. (2026) · Emergency Medicine Journal · doi:10.1136/emermed-2025-215433 · Cited by 2
“6 29 30 Addressing these barriers is crucial for maximising the impact of community-based emergency care models.”
Ramesh, S., & Umapathy, S. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01091-7 · Cited by 3
Nanziri, A., Abaatyo, J., Muwanguzi, M., Wakweyika, G., Kaggwa, M. M., & Rukundo, G. Z. (2026) · Discover Public Health · doi:10.1186/s12982-026-01703-w · Cited by 3
Aryani, F., Destiani, D. P., Satibi, S., Harsanto, B., & Pradipta, I. S. (2026) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2026.2659077 · Cited by 2
“Several reviews related to MSOs have been conducted (Bahadori et al., 2024; Yenet et al., 2023); however, they focused on hospital or industrial supply chains (Iqbal et al., 2017; Mathur et al., 2018).”
Edward, M. M., & Owoicho, A. W. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2670791 · Cited by 2
Diksha, D., Ranjan, A., Kaur, S. D., Komal, K., Mathur, H., Yadav, G., Panda, B. K., Patil, N., John, O. O., Singh, A., et al. (2024) · Springer eBooks · doi:10.1007/978-981-97-3925-7_5 · Cited by 2
Nsiah, R. B., Ankamah, J., Krah, T., Yeboah, A. K., Nyarko, D., Gmanyami, J. M., Peprah, F. O., Prempeh, F., Domfeh, C. Y., Ayirebi, I., et al. (2024) · American Journal of Health Research · doi:10.11648/j.ajhr.20241206.11 · Cited by 3
Getahun, H., Belew, S., Hasen, G., Tefera, G., Mekasha, Y. T., & Suleman, S. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1420146 · Cited by 2
“Medications are costly, particularly, an Asian and African continents, where many people struggle with affordability (4).”
BackgroundAssessing the Challenges of Managing Pharmacy Services in Public Hospitals in Erbil City
Kamal, S. I., & Surji, K. M. (2025) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-162251 · Cited by 2
“Finally, budgetary constraints are considered the basic root of numerous challenges, limiting access to resources and adversely impacting healthcare quality (22-25).”
Edith, N., Mpirirwe, R., & Kiguba, R. (2024) · Research Square · doi:10.21203/rs.3.rs-5353161/v1 · Cited by 2
Prassanna Tulasi, A., Ahmad, I., Dehury, R. K., & Behera, M. R. (2024) · Asia Pacific Journal of Health Management · doi:10.24083/apjhm.v19i3.1697 · Cited by 1
Birhanu, S., Tamiru, M. T., Kedir, H. M., & Tadesse, T. A. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00408-7 · Cited by 1
“In Addis Ababa, disparities in medicine availability between the public and private sectors have been documented, reflecting broader challenges in healthcare service delivery and resource allocation [11].”
Tey, S. W., Rajiah, K., Maharajan, M. K., Zakaria, N. B., & Ishak, N. H. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22060817 · Cited by 1
Deficiency of Clinical Trials on Endocrine Disorders: Perspectives from Sub-Saharan Africa
Azeez, T. A. (2025) · Nigerian Journal of Medicine · doi:10.4103/njm.njm_22_25 · Cited by 1
Alemayehu, T. T., Geremew, G. W., Gebremeskel, E. D., Bayleyegn, Z. W., Fitgu, A. E., Minwagaw, T., Tagele, M. J., Abebe, R. B., Zeleke, T. K., Bekalu, A. F., et al. (2025) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2025.100639 · Cited by 4
Access to essential medicines in aspirational districts of India; A multi-site cross sectional study
Meher, B. R., Padhy, B. M., & Mohanty, R. R. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_368_25 · Cited by 1
Asio, L., Besigye, I. K., Puleh, S. S., Nazziwa, N., & Ocan, M. (2025) · BMC Public Health · doi:10.1186/s12889-025-24545-8 · Cited by 1
“Research has shown that cost-related barriers often limit the success of health interventions in low resource settings [18].”
Abdelrahman, M., Al-Rekabi, M. D., Al-Oudah, G. A., Fayed, A. M., & Owadh, H. K. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1669176 · Cited by 1
Nasrin, N., Mumu, A. H., Pranto, A. H., & Islam, R. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103146 · Cited by 1
Fanda, R. B., Probandari, A. N., Yuniar, Y., van Gurp, M., van der Hoeven, W. G., Hendarwan, H., Trisnantoro, L., & Kok, M. O. (2026) · BMJ Global Health · doi:10.1136/bmjgh-2025-019616 · Cited by 2
Aluvilu, A. N., Sheehama, J. E. K., Shifotoka, S., Nabyonga-Orem, J., & Brhlíková, P. (2026) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2026.2643322 · Cited by 1
“…to be one of the most pressing challenges confronting African countries, and they are a major barrier to the provision of quality healthcare services, thus negatively affecting health equity and outcomes for patients in the region (Kibirige et al., 2022; Lane et al., 2024; Yenet et al., 2023).”
InfluentialAshour, A. M. (2026) · BMC Medical Education · doi:10.1186/s12909-026-09411-4 · Cited by 1
“…appropriate measures need to be put in place to support greater levels of perceived importance of the postgraduate master’s education in pharmaceutical marketing as one of the ways to reduce the shortage of qualified shortage that is cited in most of the current literature in this area [8].”
Hirpina, B., Selam, M. N., Fentie, A. M., Wale, M., Tegegne, A. M., & Abera, S. (2025) · BMC Health Services Research · doi:10.1186/s12913-024-12191-6 · Cited by 1
Kanyika, A., Mudenda, S., Daka, V., Kaonga, N., Mbao, C., Mwaba, D. K., & Matafwali, S. K. (2025) · Pharmacology & Pharmacy · doi:10.4236/pp.2025.162005 · Cited by 1
Metadata
- Authors
- Yenet, A., Nibret, G., & Tegegne, B. A.
- Affiliations
- Debre Markos University (ET)
- Corresponding author
- Yenet, Aderaw
- Nibret, Getinet
- Tegegne, Bantayehu Addis
- Venue
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2023-06
- Volume
- Volume 15
- Pages
- 443-458
- ISSN
- 1178-6981 (ISSN-L)
- PMC
- PMC10276598
- OpenAlex
- W4380630724
- Semantic Scholar
- ac3ee2843ccf5f72c24e512e988b5d506ce6a96a
- Cited by
- 202
- References
- 22
- Citations by year
- 2026: 83 · 2025: 73 · 2024: 43 · 2023: 3
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- essential medicines, drug availability, drug affordability, Africa, health care financing, drug pricing, inventory management, drug registration, intellectual property, health workforce shortage, household health expenditure, right to health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

